An interventional study of Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device in Lyme Disease, Lyme Neuroborreliosis and Lyme Arthritis, sponsored by Kasey Phifer. Terminated at 2 sites in United Kingdom. Open to participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-13.
Sponsored by Kasey Phifer · Not applicable, Interventional, and Treatment
Overview
PEMF Therapy for relief or reduction of lingering symptoms after antibiotic treatment of Lyme disease of participants in the UK.
Symptoms monitored:
Muscle ache, myalgia, muscle pain that is acutely located and/or 'wandering' (different location on different days) Aching joints Headache Fatigue, general tiredness, loss of energy, general exhaustion Mild, recurrent fever and/or chills occurring regularly Lack of oxygen in blood, feelings of 'air hunger', too high carbon dioxide levels in blood
Hypothesis Period measured and observed: 18 months (Includes before treatment, during the 4-8 weeks of treatment and post treatment)
Control Group Control Group symptoms will remain the same or increase (deteriorate or worsen) by 10-20% over the period observed.
The Control Group is not asked to nor required to abstain from any other forms of treatment during the 10 month observational period; Persons in the Control Group are free to - but not encouraged to - pursue holistic, complementary and mainstream medicine for their symptoms related to contraction of Lyme Disease and any other illness that may arise.
In the event of receiving treatment or taking medicine, this information is to be passed along for data collection in the regular surveys. This will be taken into consideration when evaluating the results of the trial and hypothesis.
Test Group Test Group symptoms will improve (be reduced or eliminated) by 50-75% over the period observed; In particular, the largest improvement will be achieved during the 8 weeks of treatment. After treatment, there may be a slight improvement of symptoms, however, the improvement achieved during treatment is expected to remain the same over the next 7.5 months following treatment with the exception of re-infection or contraction of a different disease or illness.
The Test Group is not asked to nor required to abstain from any other forms of treatment during the 10 month observational period; Persons in the Control Group are free to - but not encouraged to - pursue holistic, complementary and mainstream medicine for their symptoms related to contraction of Lyme Disease and any other illness that may arise.
In the event of receiving treatment or taking medicine, this information is to be passed along for data collection in the regular surveys. This will be taken into consideration when evaluating the results of the trial and hypothesis.
Measurement (What the Investigator is Measuring and Observing in Response to Testing) and Weighting
Measurement: 1 to 100 Scale Worsening/decline or improvement/reduction of symptoms will be measured by the information collected in the surveys. Answers to questions are given subjectively by the participants themselves on a scale of 1 to 100, with 1 being the worst possible or imaginable and 100 being the best possible or imaginable. For example, the worst imaginable answer of "1" to the question of mobility/movement would be in the event that the participant is in a wheelchair or coma. Being confined to a wheelchair is certainly more mobile than lying in a comatose state, however, the answers to each question are subjective and so the participant might believe that a wheelchair would be the worst measure of mobility for him or her.
Weighting of Answers To weight the improvement or decline respectively for each participant, the average of the first three and last three surveys will be taken. This is to rule out any possible statistical outliers or anomalies due to the participant possibly having a 'bad day' or coincidental other illness such as a head cold.
Example Question:
Rate overall energy level on a scale of 1 to 100, where 1 is the lowest imaginable and 100 is the best, pre-Lyme Disease level possible.
Example Answers:
Participant A First survey: 45 Second survey: 40 Third survey: 48 25th survey (third to last): 80 26th survey (second to last): 83 27th survey (last or final): 80
Weighting here would be calculated in the following way:
Starting point or "zero point" is the average of the first three surveys
Using this example:
No improvement would be from 44.33 to [44-44.49], an increase of approximately 0 = 0% Full recovery would be from 44.33 to 100, an increase of 55.67 = 100% Amount of improvement in the example is from 44.33 to 81, an increase of 36.67; It is then calculated 36.67 / 55.67 = 68.9%
Participant B (Example Answers) First survey: 30 Second survey: 25 Third survey: 25 25th survey (third to last): 80 26th survey (second to last): 83 27th survey (last or final): 80
Weighting here would be calculated in the following way:
Starting point or "zero point" is the average of the first three surveys
Using this example:
No improvement would be from 26.67 to [26.5-27], an increase of approximately 0 = 0% Full recovery would be from 26.67 to 100, an increase of 73.33 = 100% Amount of improvement in the example is from 26.67 to 81, an increase of 54.33; It is then calculated 54.33 / 73.33 = 74.1%
More information can be found published on the investigator's website: https://biofeedbackcentrebristol.co.uk/lyme-disease-clinical-trial/
91 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.
This study's enrollment of 20 is below the median of 100 across 49 interventional studies indexed under Lyme Disease.
Browse Lyme Disease studies →Kasey Phifer is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
Device: Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device
Control group will not receive treatment.
Manufactured by QX World Ltd. in Budapest, Hungary
Also known as: INDIGO, QXCI, QUEX S, QUEX ED
Overall Energy Levels
This is inversely describing fatigue, chronic fatigue and exhaustion which is a common symptom of Lyme Disease.
Time frame: 18 months
Myalgia
This will be described to participants in an easy-to-understand 'layman' terminology. Words here include e.g. muscle ache, soreness of muscles.
Time frame: 18 months
Joint stiffness
Stiffness, soreness and lack of range of motion in any and all joints
Time frame: 18 months
Depression
This is measuring the participant's own subjective feelings of mood and depression, not a clinical diagnosis.
Time frame: 18 months
Fever/Chills
mild, recurrent fever is a common symptom of Lyme Disease. Temperature will be measured by the participants themselves should they suffer from this.
Time frame: 18 months
Ability to Breathe
'Air Hunger' or the feeling of not getting enough oxygen when breathing
Time frame: 18 months
Encephalitis
Inflammation of the brain and/or spinal cord measured using the scan built into the software to confirm whether any is present in absence of medical diagnosis. Patients will report on symptoms of encephalitis, i.e. confusion, seizures, difficulty speaking, sudden changes in behaviour
Time frame: 18 months
Brain Fog
This is most likely due to hormone imbalance which results in depression, insomnia, confusion and other symptoms.
Time frame: 18 months
Nerve pain / damage
damage to the nerves resulting in loss of fine or gross motor skills, shooting pains along nerves
Time frame: 18 months
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Via spreadsheet and cloud sharing
Supporting information: Study protocol, Sap, Icf, Csr, Analytic code
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kasey Phifer